Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-I7 plus Bevacizumab in Recurrent Glioblastoma
NCT05191784Phase 2Unknown
- Sponsor
- Genexine
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efineptakin alfa in glioblastoma (GBM), sponsored by Genexine. Primary endpoints: Progression Free Survival at 24 months and Overall Survival at 24 months. Status: unknown.
02
Drugs
efineptakin alfa
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05191784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191784.